GSK, 980 Great West Road, Brentford, Middlesex TW8 9GS, UK.
Health Data Insight CIC, Capital Park, Fulbourn, Cambridge CB21 5BQ, UK; National Disease Registration Service, NHS Digital (NHSD), The Leeds Government Hub, 7&8 Wellington Place, Leeds LS1 4AP, UK.
Gynecol Oncol. 2022 Aug;166(2):317-325. doi: 10.1016/j.ygyno.2022.06.011. Epub 2022 Jun 22.
In patients with recurrent/advanced endometrial cancer who have progressed after first-line treatment, there are a lack of real-world data on treatment patterns, characteristics, and survival outcomes. A novel study was conducted to determine real-world treatment patterns and outcomes in England.
This non-interventional study used routine, administrative health data from the National Cancer Registration and Analysis Service in England to identify patients diagnosed with recurrent/advanced endometrial cancer between 1 January 2013 and 31 December 2018, inclusive. A cohort of patients who progressed to second-line treatment were identified as the 'immune checkpoint inhibitor-eligible second-line' cohort. The co-primary objectives were to summarise baseline demographics, disease characteristics, treatments received, and depict overall survival and time-to-next-treatment (a proxy for progression-free survival) from the start of second-line therapy using Kaplan-Meier methodology.
Overall, 12,058 patients were diagnosed with recurrent/advanced endometrial cancer; 999 patients were included in the immune checkpoint inhibitor-eligible second-line cohort and 77.9% (778 of 999) had advanced disease (Stage III/IV). The most common treatments received at second-line were carboplatin plus paclitaxel (27.9%), carboplatin plus liposomal doxorubicin (14.1%), liposomal doxorubicin monotherapy (13.0%), and paclitaxel monotherapy (11.6%). From initiation of second-line therapy, median (95% confidence interval) overall survival was 10.3 months (9.2-11.1), and median time-to-next-treatment was 7.7 months (7.1-8.2).
Treatments received in the relapsed setting were variable and survival outcomes poor at second-line, highlighting the need for standard of care guidance and innovative therapies to improve patient outcomes in England and in countries with similar treatment patterns.
GSK.
在一线治疗后进展的复发性/晚期子宫内膜癌患者中，缺乏关于治疗模式、特征和生存结果的真实世界数据。一项新的研究旨在确定英国的真实世界治疗模式和结果。
这项非干预性研究使用了英国国家癌症登记和分析服务处的常规行政健康数据，以确定 2013 年 1 月 1 日至 2018 年 12 月 31 日期间诊断为复发性/晚期子宫内膜癌的患者。将进展至二线治疗的患者队列确定为“免疫检查点抑制剂合格的二线”队列。主要目的是使用 Kaplan-Meier 方法总结基线人口统计学、疾病特征、接受的治疗，并描述从二线治疗开始的总生存期和下一次治疗时间（无进展生存期的替代指标）。
总体而言，12058 名患者被诊断为复发性/晚期子宫内膜癌；999 名患者被纳入免疫检查点抑制剂合格的二线队列，其中 77.9%（778/999）为晚期疾病（III/IV 期）。二线治疗中最常见的治疗方法是卡铂加紫杉醇（27.9%）、卡铂加脂质体多柔比星（14.1%）、脂质体多柔比星单药治疗（13.0%）和紫杉醇单药治疗（11.6%）。从二线治疗开始，中位（95%置信区间）总生存期为 10.3 个月（9.2-11.1），下一次治疗时间的中位值为 7.7 个月（7.1-8.2）。
在复发环境中接受的治疗方法多种多样，二线治疗的生存结果较差，这突显了需要有标准的护理指导和创新疗法，以改善英国和具有类似治疗模式的国家的患者预后。
葛兰素史克公司。
Zotero 插件